知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

90 条记录 (耗时 0.031 秒)

    Prevention and treatment of restenosis by local administration of drug
    13.
    发明申请
    Prevention and treatment of restenosis by local administration of drug 有权
    通过局部药物治疗预防和治疗再狭窄

    公开(公告)号：US20030109442A1

    公开(公告)日：2003-06-12

    申请号：US10260094

    申请日：2002-09-27

    申请人： Esperion Therapeutics, Inc. ,  Cedars-Sinai Medical Center

    发明人： Charles L. Bisgaier ,  Prediman Krishan Shah ,  Sanjay Kaul

    IPC分类号： A61K038/17

    CPC分类号： A61K38/17 ,  Y02A50/406 ,  Y02A50/465 ,  Y02A50/467

    摘要： Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally before or during bypass surgery on diseased coronary, peripheral, and cerebral arteries, surgery to implant grafts or transplanted organs, or angioplasty, or to stabilize unstable plaques. In an alternative embodiment, the apolipoprotein is not provided directly, but the gene encoding the apolipoprotein is provided. The gene is introduced into the blood vessel in a manner similar to that used for the protein, where the protein is then expressed. The technique can also be used for delivery of genes for treatment or prevention or restenosis or other cardiovascular diseases. In yet another embodiment, stents are coated with apolipoproteins alone, apolipoproteins formulated with lipids, genetically engineered cells expressing the apolipoproteins, naked DNA coding for an apolipoprotein, or other drugs such as anti-proliferatives for local delivery to an injury site. In a preferred embodiment, the system is used with combination therapy, with for local delivery of an agent such as an apolipoprotein in combination with systemic antihypertension therapy, anti-inflammatoy therapy, lipid regulation and/or anti-coagulation therapy. These treatments can begin prior to, concurrent with or following local delivery.

    摘要翻译： 单独或更优选与脂质载体如磷脂或其它药物组合的载脂蛋白AI（ApoA-I），优选载体载体蛋白AI Milano（ApoA-IM）的变体形式可以在旁路手术之前或期间局部施用 患病冠状动脉，外周动脉和脑动脉，植入移植物或移植器官的手术或血管成形术，或稳定不稳定斑块。 在替代实施方案中，载脂蛋白不是直接提供的，而是提供编码载脂蛋白的基因。 将该基因以与用于蛋白质的蛋白质相似的方式引入血管中，然后蛋白质被表达。 该技术还可用于递送用于治疗或预防或再狭窄或其它心血管疾病的基因。 在另一个实施方案中，支架单独用载脂蛋白包被，用脂质配制的载脂蛋白，表达载脂蛋白的遗传工程改造的细胞，编码载脂蛋白的裸露的DNA，或用于局部递送至损伤部位的其它药物如抗增殖物。 在优选的实施方案中，该系统与联合治疗一起使用，用于局部递送诸如载脂蛋白的药物与全身性抗高血压治疗，抗炎疗法，脂质调节和/或抗凝治疗的组合。 这些治疗可以在本地分娩之前，同时或之后开始。